That sounds like something from a fortune cookie :- )
Seriously, I’m not sure what Waksal and his partners see, if anything, in the HCV part of Three Rivers’ portfolio, which strikes me as a collection of useless compounds.
VRX was willing to part with this gem for $5M up-front and an 8-12% royalty on sales (that will probably never occur). I wonder what Sam is smoking :- )